Dr. Malcolm K. Brenner This is Me

Education

 View all 154 references Web References

1. 1. Texas Children's Cancer Center - Our Faculty - Malcolm K. Brenner, M.D., Ph.D.

   www.txccc.org/content.cfm?cont - [Cached]

   Published on: 7/1/2008   Last Visited: 7/1/2008

   Malcolm K. Brenner, M.D., Ph.D.Texas Children's Cancer Center - Our Faculty - Malcolm K. Brenner, M.D., Ph.D.
   ...
   Malcolm K. Brenner, M.D., Ph.D.
   ...
   One interest of Dr. Brenner's research is in the field of tumor immunology.Tumor cells that have been genetically modified to express immunostimulatory genes will induce effective anti-tumor responses in a range of syngeneic animal models.Dr. Brenner has compared the relative immunostimulatory and anti tumor potency of autologous and allogeneic tumor vaccines in children with advanced neuroblastoma and in adult with acute and chronic leukemia.Recipients of both autologous and allogeneic vaccines showed evidence of local immunity but the autologous vaccine showed more potent systemic activity.In follow up studies, the immunogenicity of the tumor cells was increased by transducing them with a combination of lymphotactin, a T lymphocyte chemotaxin, and IL2, to amplify the response of tumor specific T cells attracted to the site of tumor inoculation.This approach has been extended to individuals with minimal residual disease.Similar studies are also underway in patients with acute and chronic leukemia.Dr Brenner's laboratory is also using molecular techniques to increase the effectiveness of cytotoxic T cell killing of tumor cells.
   
   Dr Brenner is Associate Editor of Blood and of Molecular Therapy and the Principal Investigator or Co-investigator on 5 NIH grants.

2. 2. www.asgt.org

   www.asgt.org/am07/asgt_news/pa - [Cached]

   Published on: 8/16/2007   Last Visited: 8/16/2007

   Malcolm Brenner
   ...
   Malcolm K. Brenner, M.D., Ph.D.
   
   Malcolm K. Brenner, M.D., Ph.D., Director, Shell Center for Gene Therapy, Baylor College of Medicine, and former ASGT president.His talk was titled Implementing Gene Therapies for Complex Disorders, and it focused on gene therapy for cancers.
   
   Despite setbacks, recent successful pivotal clinical trials have encouraged continued investigation aimed at exploring T-cell immunity against cancer.In addition, recent improvements in cellular biology and the ability to manipulate gene expression in cells of the immune system have facilitated and enhanced efforts aimed at developing these therapies for malignant disease.
   
   Dr. Brenner described a series of iterative clinical and laboratory studies that led to the use of a gene transfer protocol to develop a T-cell based therapy for both hematological and epithelial malignancies.He said that when these cells are processed correctly and given back to the patients, they experience a "measurable rise" in their number of tumor-specific T cells, which is associated with tumor responses.
   
   Although many challenges remain, the significant response rates (including many sustained complete remissions) that have been attained, even in patients with relapsed or primary resistant disease, is very encouraging."We regularly see complete responses both in lymph node disease and also in patients with solid organ disease with this approach," said Dr. Brenner."So, it is very exciting."
   
   Despite these accomplishments, Dr. Brenner warned that the myriad of regulatory hurdles that must overcome is becoming an "ever rising" barrier that is delaying the investigation and translation of effective gene based immune therapies.He suggested that the many federal and local regulatory agencies that gene therapy researchers have to obtain permission from be reduced to a single federal regulatory agency and a single local regulatory agency.

3. 3. MaxCyte | Applications - Immunotherapy

   www.maxcyte.com/immunotherapy. - [Cached]

   Published on: 2/15/2008   Last Visited: 4/23/2008

   Malcolm K. Brenner, Director and Professor, Baylor College of Medicine -Immunotherapy Case Study [Click Here]